Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
Reizine N, Danahey K, Schierer E, Liu P, Middlestadt M, Ludwig J, Truong TM, van Wijk XMR, Yeo KJ, Malec M, Ratain MJ, O'Donnell PH.
Reizine N, et al.
Oncologist. 2021 Nov;26(11):e2042-e2052. doi: 10.1002/onco.13953. Epub 2021 Sep 19.
Oncologist. 2021.
PMID: 34423496
Free PMC article.
This study showed that patients with cancer frequently receive CYP2D6-dependent opioids. However, patients with CYP2D6 intermediate and poor metabolizer status had increased numbers of pain-related hospitalizations and more frequently required the pote …
This study showed that patients with cancer frequently receive CYP2D6-dependent opioids. However, patients with CYP2D6 …